Skip to main content

Table 1 Characteristics of patients with rheumatoid arthritis (RA) and osteoarthritis (OA)

From: Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis

Characteristics

RA (n = 40)

OA (n = 34)

Gender (female/male)

27/13

25/9

Age (years)

54.90 ± 14.25

65.21 ± 10.41

CRP (mg/l)

27.88 ± 31.80

4.11 ± 4.30

Disease duration (years)

6.72 ± 8.58

5.57 ± 7.41

Drugs (DMARDs/GCs)

37/26

-

Biological therapy

8a

-

DAS28

4.39 ± 1.19

-

RF positivity, n (%)

31 (72%)

-

Anti-CCP positivity, n (%)

26 (60%)

-

  1. Data are expressed as the mean (± SD) unless stated otherwise. aOut of 8 patients, 5 were treated with anti-TNF therapy, 1 with tocilizumab, 1 with rituximab and 1 with anti-IL-17 therapy. Anti-CCP anti-cyclic citrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, DAS28 disease activity score in 28 joints, DMARDs disease-modifying antirheumatic drugs, GCs glucocorticoids, MTX methotrexate, RF rheumatoid factor, SJC swollen joints count